Sartorius AG (FRA:SRT3) has been given a consensus recommendation of “Sell” by the nine ratings firms that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is €146.50 ($170.35).

A number of equities analysts recently commented on SRT3 shares. Deutsche Bank set a €170.00 ($197.67) price target on Sartorius and gave the company a “neutral” rating in a research note on Monday, July 22nd. HSBC set a €150.00 ($174.42) price objective on Sartorius and gave the stock a “neutral” rating in a research note on Friday, July 12th. Nord/LB set a €125.00 ($145.35) price objective on Sartorius and gave the stock a “sell” rating in a research note on Monday, July 22nd. Warburg Research set a €184.00 ($213.95) price objective on Sartorius and gave the stock a “neutral” rating in a report on Tuesday, July 23rd. Finally, Berenberg Bank set a €145.00 ($168.60) target price on Sartorius and gave the company a “sell” rating in a research report on Thursday, July 25th.

SRT3 traded up €2.20 ($2.56) on Friday, reaching €170.20 ($197.91). The company had a trading volume of 46,873 shares. Sartorius has a fifty-two week low of €71.00 ($82.56) and a fifty-two week high of €124.70 ($145.00). The company’s fifty day moving average is €179.09 and its 200 day moving average is €168.20.

Sartorius Company Profile

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Further Reading: Net Margin

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.